MedTrace Logo

Efficacy and Safety of Lambdalina (Lidocaine Cream) Versus Placebo as an Anesthetic for Laser Hair Removal

NCT01360749 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2012-04-13

No results posted yet for this study

Summary

Double-blind, randomized, placebo-controlled trial to assess the efficacy of Lambdalina (lidocaine cream) in reducing pain associated with laser hair removal in women.

Conditions

  • Local Anesthesia

Interventions

DRUG

Lambdalina® (Lidocaine 4% cream)

Lambdaline dose: 2 g for 10 cm2.

DRUG

Placebo

Placebo dose: 2 g for 10 cm2.

Sponsors & Collaborators

  • ISDIN

    lead INDUSTRY

Principal Investigators

  • Antonio Campo Voegeli, MD · Clínica Dermatológica Campo De Felipe, Barcelona, Spain

  • Serafín Fernández, MD · Clínica Dermatológica Láser, Madrid, Spain

  • Antonio Campo Voegeli, MD · Clínica Dermatológica Campo De Felipe, Barcelona, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01360749 on ClinicalTrials.gov